Citi Sees Abbott Undervalued as Stock Dips to $88.41
4h ago|4 min readStandard
Fazen Markets Editorial Desk
Collective editorial team · methodology
abbott-laboratoriesabt
Fazen Markets Editorial Desk
Collective editorial team · methodology
Trades XAUUSD 24/5 on autopilot. Verified Myfxbook performance. Free forever.
Risk warning: CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. The majority of retail investor accounts lose money when trading CFDs. Vortex HFT is informational software — not investment advice. Past performance does not guarantee future results.
In a note published on June 19, 2026, analysts at Citi argued that the market is undervaluing Abbott Laboratories (ABT) relative to the strength of its underlying business segments. The note was released as Abbott's stock traded at $88.41, representing a decline of 2.44% for the day as of 08:14 UTC today, within a range of $87.76 to $89.44. Citi's perspective highlights a potential valuation gap for a diversified healthcare giant currently commanding a market capitalization of approximately $155 billion. This analysis arrives during a period of heightened volatility for medical technology stocks, prompting a reassessment of fundamental value drivers.
The assessment from Citi gains immediate relevance due to recent sector-wide pressure on healthcare valuations. The iShares U.S. Medical Devices ETF (IHI) has declined 4.8% over the past month, underperforming the broader S&P 500's 1.2% gain over the same period. This underperformance reflects investor concerns over regulatory headwinds and potential changes to elective procedure volumes amid economic uncertainty. Historically, Abbott has demonstrated resilience during such market phases; during the market correction of late 2025, ABT shares fell 9.5% from peak to trough, less than the 13.2% drop for the medical device peer group index. The immediate catalyst for Citi's note appears to be the stock's recent pullback, which the firm believes has created a more attractive entry point detached from strong segment fundamentals, particularly in diagnostics and medical devices.
Current market data shows Abbott trading at a forward price-to-earnings (P/E) ratio of 20.3, a discount to its 5-year average of 22.1. This valuation persists despite the company forecasting segment-level organic sales growth between 5.5% and 7.0% for the 2026 fiscal year. A peer comparison reveals significant valuation discrepancies.
| Metric | Abbott (ABT) | Boston Scientific (BSX) | Medtronic (MDT) |
|---|---|---|---|
| Forward P/E | 20.3x | 24.1x | 16.8x |
| YTD Price Change | -5.2% | +3.1% | -8.7% |
Abbott's market capitalization of $155.1 billion is supported by a diversified revenue base: Medical Devices ($17.8B annual run-rate), Diagnostics ($10.5B), Established Pharmaceuticals ($5.4B), and Nutrition ($7.2B). The stock's current price of $88.41 sits above its 200-day moving average of $86.12 but below its 50-day average of $90.45, indicating short-term technical weakness. Its year-to-date decline of 5.2% contrasts with the Health Care Select Sector SPDR Fund's (XLV) 0.3% gain.
Citi's undervaluation thesis implies a potential rerating for Abbott that could ripple through related healthcare subsectors. A sustained move higher in ABT would likely provide support for peers like DexCom (DXCM) and Stryker (SYK), which trade at premiums of 38.5x and 23.4x forward earnings, respectively. Conversely, more direct competitors like Medtronic (MDT) may see increased scrutiny on its own valuation at 16.8x earnings. The primary counter-argument is that Abbott's recent growth has been partially fueled by pandemic-related diagnostics sales, a revenue stream that has normalized and now faces difficult year-over-year comparisons. Institutional positioning data from the prior quarter shows hedge funds were net sellers of ABT, trimming aggregate exposure by approximately 2.7 million shares, while long-only funds remained steady. Recent options flow suggests increased buying of out-of-the-money calls expiring in September, indicating some traders are positioning for a potential rebound.
The next major catalyst for Abbott is its second-quarter 2026 earnings report, scheduled for July 23, 2026. Guidance for full-year organic growth and margin expansion within the Medical Devices segment will be critical to validating the undervaluation argument. Investors should monitor the $86.50 support level, which aligns with the stock's 2026 low, and resistance near $92.00, its early-May peak. Regulatory updates from the FDA on key pipeline devices, including the next-generation MitraClip system, are expected in the third quarter. The broader market's reaction to the next Federal Reserve FOMC statement on July 29 will also influence sector-wide risk appetite. If Abbott's Q2 earnings demonstrate sustained device sales growth exceeding 8%, it could trigger a reassessment of the stock's multiple. Conversely, a miss on diagnostics revenue or a lowering of annual EPS guidance would likely pressure shares toward the $85 level.
It means analysts believe the company's total stock price does not fully reflect the combined value and growth prospects of its individual operating divisions. Citi's view suggests that if Abbott's four main segments—Medical Devices, Diagnostics, Nutrition, and Established Pharmaceuticals—were valued independently and summed, the total would exceed the current $155 billion market cap. This is often a call for sum-of-the-parts analysis, a valuation method where each business unit is valued separately, often using peer company multiples.
Analyst calls vary in reliability based on the firm's historical accuracy and the depth of supporting research. Citi has maintained a 'Buy' or equivalent rating on Abbott since 2021. Over a 12-month horizon following similar 'undervalued' calls from major banks on large-cap healthcare stocks since 2022, the target stock outperformed its sector index 60% of the time, with a median outperformance of 4.2 percentage points. However, these calls can be wrong if sector headwinds intensify or company-specific execution falters.
Abbott provides detailed quarterly and annual financial results for each of its four reportable segments on the Investor Relations section of its corporate website. This data includes revenue, operating earnings, and growth rates for Medical Devices, Diagnostics, Nutrition, and Established Pharmaceuticals. Investors can use this for direct comparison against pure-play public competitors in each segment to conduct their own sum-of-the-parts valuation. For broader market context on healthcare valuations, Fazen Markets publishes regular sector analysis.
Citi's analysis posits Abbott's recent stock price weakness creates a buying opportunity based on the underlying strength of its diversified healthcare businesses.
Disclaimer: This article is for informational purposes only and does not constitute investment advice. CFD trading carries high risk of capital loss.
Vortex HFT is our free MT4/MT5 Expert Advisor. Verified Myfxbook performance. No subscription. No fees. Trades 24/5.
Position yourself for the macro moves discussed above
Start TradingSponsored
Open a demo account in 30 seconds. No deposit required.
CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.